AstraZeneca boss ‘wants to shift stock market listing to US'
The boss of Britain's most valuable listed company has spoken privately about a preference to move the listing to New York, the Times reported. It added that he had also considered moving the company's domicile.
The FTSE 100 company's share price rose by 2.8% on Tuesday, with most of the increase happening after the story was published.
A shift in AstraZeneca's listing would deal a major blow to the London Stock Exchange, which has already had to deal with a series of departures by companies seeking higher valuations. Among those who have left the FTSE 100 in recent years are equipment rental company Ashtead, Paddy Power bookmaker owner Flutter Entertainment, building materials supplier CRH and packaging company Smurfit Westrock.
A shift by AstraZeneca would almost certainly face opposition by the UK government, although it would not have the power to formally block a move. Labour made life sciences one of its key growth sectors in its industrial strategy published last month.
A spokesperson for AstraZeneca declined to comment.
AstraZeneca is thought to have expressed frustrations privately with the rejection of its breast cancer drug, Enhertu, by the NHS on cost grounds. Earlier this year, the company, headquartered in Cambridge, caused consternation in government by pulling out of a £450m project to produce vaccines in Speke, Liverpool, while saying that the business case did not make sense without more financial support from government.
Soriot has overseen the market value of AstraZeneca more than tripling since he took over in October 2012. The company has overtaken oil company Shell – also seen as a contender for a move to the US – and HSBC, a bank, with a market value of £157bn.
The US is the world's biggest pharmaceutical market, with by far the highest spending per person on medicines despite having a lower life expectancy than several other countries. UK executives have long complained that their companies are undervalued compared with American counterparts.
Sign up to Business Today
Get set for the working day – we'll point you to all the business news and analysis you need every morning
after newsletter promotion
Soriot has emphasised the company's ambitions to grow in the US. In November, he told investors that 'we want to see even more growth in the US over the next few years as part of our 2030 ambition,' according to a transcript from data company Alphasense. The 'US is, of course, a very important market and that supports innovation, and we will continue to invest to grow fast in this part of the world,' Soriot said.
The chief executive's pay has increased in line with AstraZeneca's market value. He has been the highest-paid chief executive on the FTSE 100 for two years running, receiving £16.85m for 2023, up from £15.3m in 2022.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Times
12 minutes ago
- Times
Tally of growth businesses selling up nears 8,000 in 10 years
The number of high-growth businesses choosing to sell up has hit almost 8,000 over the past ten years as founders sell their companies to corporates or float their enterprises on public markets. Acquisitions have accounted for the majority of business exits over the period, according to analysis by Charles Stanley, the investment management firm. Deals peaked in the year after the pandemic, with 1,110 acquisitions taking place. Corporate buyers accounted for 956 purchases and financial buyers for 154 purchases. The firm's research also found that almost 40 per cent of the exit activity has occurred in the last two and a half years. Cliadhna Law, head of direct and professional sales at Charles Stanley, said: 'Acquisitions remain the dominant form of exit, driven by both corporate and financial buyers, and IPOs, although less frequent, are important for high-growth firms seeking public capital and global visibility. 'A more stable exit landscape may be on the horizon, one defined by sustained acquisition activity and signs of a potential recovery in the IPO market. These changes reflect the UK's increasingly flexible approach to value realisation and the changing priorities of founders, investors, and buyers across the high-growth ecosystem.' The City is hopeful for a more sustained pick-up in company listings after it emerged Visma, a private equity-backed business software group, is considering a market debut in London. The group is based in Oslo, Norway, and has been valued at around €19 billion. Visma's potential listing comes after a number of large companies moved their listings away from London to New York, including Ashtead, the industrial equipment hire firm, Flutter, the owner of Paddy Power, CRH, the building materials supplier, and Ferguson, the plumbing group. Nikhil Rathi, chief executive of the City regulator, the Financial Conduct Authority, told business leaders last month that there was a need to 'reset the psychology' and 'put aside British modesty and celebrate' the strengths of UK markets. In a speech in the City, he said: 'We have world-leading banking, insurance, derivatives, debt, foreign exchange and commodity markets and infrastructure. We lead Europe in fintechs and are second only to the US in investment management.'
Telegraph
31 minutes ago
- Telegraph
The conditions are just right for this airline owner to soar
Questor is The Telegraph's stock-picking column, helping you decode the markets and offering insights on where to invest. Even after soaring by 107pc since our initial 'buy' recommendation in February 2021, shares in British Airways owner IAG continue to trade on a dirt-cheap valuation. The FTSE 100-listed company, which also owns several other airlines including Iberia, Vueling and Aer Lingus, has a price-to-earnings ratio of just 7.1 at a time when the UK's large-cap index trades very close to a record high. The firm's near-term financial forecasts do little to help justify its bargain basement price level. While investors may naturally expect such a lowly-valued stock to have a deteriorating bottom line, its earnings per share are set to rise by 12pc this year and by a further 8pc next year. Indeed, as a highly cyclical firm, IAG is well placed to benefit from the full effect of sustained monetary policy easing across its key markets of the US, Eurozone and the UK. Due to the existence of time lags, interest rate cuts enacted thus far by central banks in all three geographies are yet to have their maximum impact on economic growth or wage increases. And with sticky inflation widely expected to dissipate over the medium term, a likely continuation of recent monetary policy easing could lead to rising spending power among consumers that prompts higher demand for international air travel. In fact, passenger numbers for the global airline industry are forecast to rise by 5.8pc this year. They are also expected to double from their pre-pandemic level of four billion people per year to roughly eight billion people per year by 2040. With IAG having a well-diversified business model, it is in a relatively strong position to capitalise on an upbeat long-term industry outlook. Its portfolio of airlines equates to a greater variety of geographies covered and, perhaps more importantly, a wider range of price points vis-à-vis its rivals. For example, it is not limited to European budget short-haul operations as per some of its sector peers. A diverse range of operations could prove particularly useful should an uncertain outlook caused by the global trade war lead to temporary economic difficulties. Given that the firm had total liquidity of around €12.4bn (£10.5 bn) at the end of March this year, while net interest costs were covered more than eight times by operating profits last year, it is well placed to overcome the inherent ups-and-downs of the economic cycle. The company's latest quarterly results, meanwhile, showed that it continues to reinvest for long-term growth. As well as reporting a first-quarter rise in sales of 9.6pc and an operating profit of €198m, versus just €68m in the same period from the prior year, the firm announced that it has ordered 53 new wide-body aeroplanes. It also confirmed that it is making progress with a €1bn share buyback programme that was announced earlier this year. Share repurchases that are set to take place over the coming months should have a positive impact on the company's share price. Given its dirt-cheap market valuation, a share buyback programme appears to be a highly logical use of excess cash. While a dividend yield of just 2.2pc, alongside the company's highly cyclical status, means its income appeal is somewhat limited, fast-paced earnings growth could lead to a brisk pace of increase in shareholder payouts over the coming years. As mentioned, IAG's share price has more than doubled since our initial 'buy' tip in February 2021. In doing so, it has outperformed the FTSE 100 index by 82 percentage points. In the short run, the company's cyclical status means its shares could be severely affected by news updates regarding the ongoing global trade war. While this may equate to elevated volatility, Questor remains highly upbeat about the stock's long-term capital growth potential. This is largely due to the vast margin of safety offered by its shares. Investors appear to be materially undervaluing the firm's growth prospects as the impact of falling interest rates, as well as modest inflation, become more evident. With IAG having a solid financial position through which to overcome potential near-term challenges, and it reinvesting heavily ahead of a likely continued improvement in its industry outlook, the stock remains a worthwhile purchase. Questor says: buy Ticker: IAG Share price at close: 343.1p
The Independent
34 minutes ago
- The Independent
Digital ‘one stop shop' for NHS will speed up care for patients, Government says
A new 'one stop shop' will showcase cutting-edge technologies to NHS hospitals while also slashing red tape, the Government has announced. The digital platform – MedTech Compass – aims to bring together technologies that are good for patients with an 'innovator passport' to cut the time firms spend on making repetitive data submissions to NHS trusts. The aim, set out in this week's 10-year plan for the NHS, is to get technology into the hands of NHS staff and patients quicker than before. Health and Social Care Secretary Wes Streeting said: 'For too long, Britain's leading scientific minds have been held back by needless admin that means suppliers are repeatedly asked for the same data in different formats by different trusts – this is bad for the NHS, patients and bad for business. 'These innovator passports will save time and reduce duplication, meaning our life sciences sector – a central part of our 10-Year Health Plan – can work hand-in-hand with the health service and make Britain a powerhouse for medical technology. 'Frustrated patients will no longer have to face a postcode lottery for life-saving products to be introduced in their area and companies will be able to get their technology used across the NHS more easily, creating a health service fit for the future under the Plan for Change.' Writing in The Independent, Mr Streeting said the plan would put nursing at the heart of transforming the NHS, including training them on the latest technology and help 'shift our NHS from analogue to digital'. He said plans would cut red tape to enable nurses to start working on wards quickly after finishing training, faster payment of expenses and training in communities. The passport will be introduced over the next two years and will mean technology that has been robustly assessed by one NHS organisation can easily be rolled out to others. The Department of Health said this would remove 'needless bureaucracy' and create a 'dynamic best buyer's guide', while also helping boost economic growth. In on example, special wound dressings which are already cutting infections after surgery by 38% at Barking, Havering & Redbridge University Hospitals could be adopted across the country, the Department said. Meanwhile, at Barts Health Trust in London, the use of antimicrobial protective coverings for cardiac devices have cut infections and saved more than £103,000 per year. The Department of Health also said rapid flu testing at University Hospitals Dorset has cut the time patients spend in hospital alongside antibiotic use – something that could benefit other hospitals. MedTech Compass aims to make these innovations, and the evidence underpinning them, clearer to buyers within the NHS. Dr Vin Diwakar, clinical transformation director at NHS England, said: 'We're seeing the impact improvements to technology are having on our everyday lives on everything from smartwatches to fitness trackers – and we want to make sure NHS patients can benefit from the latest medical technology and innovations as well. 'The new innovator passports will speed up the rollout of new health technology in the NHS which has been proven to be effective, so that patients can benefit from new treatments much sooner.' Chief executive of NHS Providers, Daniel Elkeles, said: 'We welcome any measures which cut red tape and help trusts get proven and effective technology onto the frontline faster to boost patient care and free staff from time-consuming admin.' Professor Peter Bannister, medtech expert and fellow at the Institution of Engineering and Technology (IET), said: 'This centralisation and simplification of adoption across the NHS will be welcomed by industry – including both large corporates and innovative UK small businesses – as well as by patients and clinicians. 'However, there must be clear evidence standards for manufacturers that recognise the diversity and health inequalities of the UK population, while the variation in digital readiness and workforce skills between different healthcare providers must also be factored in.'
